July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Patient Journey After Intensification of Topical Glaucoma Therapy - a US Claims-Based Analysis
Author Affiliations & Notes
  • Anik Patel
    Allergan, Newport Beach, California, United States
  • Gail Schwartz
    Glaucoma Consultants, Baltimore, Maryland, United States
  • Joanna Campbell
    Allergan, Newport Beach, California, United States
  • Chi-Chang Chen
    QuintilesIMS, Pennsylvania, United States
  • Catherine McGuiness
    QuintilesIMS, Pennsylvania, United States
  • Oluwatosin Smith
    Glaucoma Associates of Texas,, Texas, United States
  • Footnotes
    Commercial Relationships   Anik Patel, Allergan (E); Gail Schwartz, Aerie (R), Allergan (R), Allergan (C); Joanna Campbell, Allergan (E); Chi-Chang Chen, QuintilesIMS (E); Catherine McGuiness, QuintilesIMS (E); Oluwatosin Smith, Aerie (R), Alcon (C), Allergan (C), Allergan (R), Bausch + Lomb (R), Glaukos (C), Gore (C), IRIDEX (C), New World Medical Inc (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4465. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Anik Patel, Gail Schwartz, Joanna Campbell, Chi-Chang Chen, Catherine McGuiness, Oluwatosin Smith; Patient Journey After Intensification of Topical Glaucoma Therapy - a US Claims-Based Analysis. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4465.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the treatment journey of patients receiving multiple topical glaucoma medications (TGMs) for management of open-angle glaucoma (OAG) or ocular hypertension (OHT).

Methods : This was a retrospective analysis of administrative claims data (Jan 2011 - July 2017) from the IQVIA PharMetrics Plus database. The study included patients ≥40 years with a diagnosis of OAG/OHT who underwent treatment intensification with ≥1 TGM of a different drug class during Jan 2012 - July 2015 (index period). For inclusion, patients had to be continuously enrolled for ≥12 months before and ≥24 months after the start (‘index’) date of their first intensified treatment regimen. Patients with prior OAG surgery, or the same or higher number of TGMs during the pre-index period, were excluded.

Results : In total, 48,402 patients (mean [SD] age 61.4 [9.6] years) underwent treatment intensification during the index period; of these, 22,874 (47.3%), 16,214 (33.5%), 7,137 (14.7%) and 2,177 (4.5%) received a 1st, 2nd, 3rd or 4th TGM class, respectively, as their first observed intensified regimen (‘index drop combination’). Among the cohorts receiving 1, 2, 3 or 4 TGMs as their index drop combination, 7.8%, 12.2%, 17.1% and 22.5% of patients, respectively, had subsequent treatment augmentation (TGM addition or glaucoma procedure, laser or surgical) during the first 12 months post-index, rising to 12.6%, 18.5%, 25.9% and 33.6%, respectively, during the first 24 months. Conversely, 20.7% and 26.4% of all patients, respectively, had discontinued TGM treatment but had not had a glaucoma procedure at 12 and 24 months post-index. Median time to TGM augmentation declined with each additional TGM in the index drop combination: 176, 136, 106 and 106.5 days for the 1st, 2nd, 3rd and 4th TGM, respectively. Overall, 19.6% and 29.1% of patients had de novo ocular surface disease (OSD) diagnosis and/or treatment in the first 12 and 24 months, respectively.

Conclusions : Multiple drop therapy brings shorter-lasting benefit with each additional agent and often quickly escalates to encompass surgical and laser procedures. Drop therapy is also associated with a substantial incidence of OSD.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

Rates of treatment augmentation, treatment discontinuation, and OSD, categorized by index drop combination

Rates of treatment augmentation, treatment discontinuation, and OSD, categorized by index drop combination

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×